Alterity Therapeutics (NASDAQ:ATHE) Lowered to “Hold” Rating by Benchmark

Benchmark lowered shares of Alterity Therapeutics (NASDAQ:ATHE) from a speculative buy rating to a hold rating in a research report sent to investors on Monday morning, Marketbeat Ratings reports.

Separately, Maxim Group upped their target price on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, January 30th.

Alterity Therapeutics Trading Up 4.0 %

ATHE stock opened at $4.99 on Monday. Alterity Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.87. The business’s 50 day moving average price is $2.86 and its two-hundred day moving average price is $1.85.

Institutional Trading of Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC increased its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.